| Identification | Back Directory | [Name]
Urea, N-[(1R)-2,3-dihydro-2',4'-dioxo-3'-[2-oxo-2-[(3R)-1,3,4,5-tetrahydro-3-methyl-2H-2-benzazepin-2-yl]ethyl]spiro[1H-indene-1,5'-oxazolidin]-5-yl]-N'-methyl- | [CAS]
2379409-91-1 | [Synonyms]
CBP/p300-IN-15
Urea, N-[(1R)-2,3-dihydro-2',4'-dioxo-3'-[2-oxo-2-[(3R)-1,3,4,5-tetrahydro-3-methyl-2H-2-benzazepin-2-yl]ethyl]spiro[1H-indene-1,5'-oxazolidin]-5-yl]-N'-methyl- | [Molecular Formula]
C26H28N4O5 | [MOL File]
2379409-91-1.mol | [Molecular Weight]
476.52 |
| Hazard Information | Back Directory | [Uses]
CBP/p300-IN-15 (compound 13a) is a potent p300/CBP inhibitor, with IC50 values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC50 values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research[1]. | [IC 50]
CBP: 28 nM (IC50); p300: 2.5 nM (IC50) | [References]
[1] Ding H, et al. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer. Bioorg Med Chem. 2021 Dec 15;52:116512. DOI:10.1016/j.bmc.2021.116512 |
|
|